Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233, China.
Hereditas. 2020 May 22;157(1):22. doi: 10.1186/s41065-020-00136-y.
Non-invasive diagnostic markers are of great importance for early screening nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) play significant roles in many metabolic disease, including NAFLD. Therefore, this study focusd on a Chinese population to explore the possible correlation between circulating miR-132 and NAFLD.
Serum miR-132 was positively associated with NAFLD in non-type 2 diabetes mellitus (T2DM) groups by logistic regression (OR = 3.082 [1.057, 8.988], P = 0.039) after adjusting age, sex, and body mass index (BMI). Additionally, in non-T2DM subgroup, after adjusting age, sex, bmi, serum miR-132 was significantly associated with ALT (β ± SE = 0.005 ± 0.002, P = 0.018), TG (β ± SE = 0.072 ± 0.029, P = 0.015), FPG (β ± SE = 0.123 ± 0.058, P = 0.036), γ-GT (β ± SE = 0.002 ± 0.001, P = 0.047), apoE (β ± SE = 0.038 ± 0.002, P = 0.017) .
Serum miR-132 was found to be associated with NAFLD risk in a Chinese cross-section study. This finding provides a prospective research direction for early screening and diagnosing NAFLD.
非侵入性诊断标志物对于非酒精性脂肪性肝病 (NAFLD) 的早期筛查非常重要。微小 RNA (miRNA) 在许多代谢性疾病中发挥着重要作用，包括 NAFLD。因此，本研究聚焦于中国人群，探索循环 miR-132 与 NAFLD 之间可能的相关性。
通过逻辑回归（调整年龄、性别和体重指数后，OR=3.082[1.057,8.988]，P=0.039），我们发现血清 miR-132 与非 2 型糖尿病（T2DM）患者的 NAFLD 呈正相关。此外，在非 T2DM 亚组中，调整年龄、性别和 BMI 后，血清 miR-132 与 ALT（β±SE=0.005±0.002，P=0.018）、TG（β±SE=0.072±0.029，P=0.015）、FPG（β±SE=0.123±0.058，P=0.036）、γ-GT（β±SE=0.002±0.001，P=0.047）和 apoE（β±SE=0.038±0.002，P=0.017）显著相关。
本横断面研究发现血清 miR-132 与 NAFLD 风险相关。这一发现为 NAFLD 的早期筛查和诊断提供了一个前瞻性的研究方向。
